阿托伐他汀对慢性心力衰竭RAAS系统与炎性因子的影响  

Effects of Atovastatin on RAAS and inflammatory cytokines in patients with chronic heart failure

作　　者：古忆[1] 周建松[1] 夏思良[1] 张颖[1] 颜京瑞[1] 王玉荣[1] 卢新政[2] 

机构地区：[1]东南大学附属南京江北人民医院,南京210048 [2]南京医科大学第一附属医院心脏科

出　　处：《临床心血管病杂志》2016年第1期94-96,共3页Journal of Clinical Cardiology

基　　金：南京市医学科技发展项目(No:YKK12212)

摘　　要：慢性心力衰竭（CHF）是以进行性左室收缩和（或）舒张功能不全为特征的临床综合征。持续性全身炎症、免疫反应激活可能是各种机制的最终致病环节。然而,关于肾素-血管紧张素-醛固酮（RAAS）系统激活、炎性细胞因子及自身免疫反应之间的内在联系却鲜有人提及。本研究对CHF患者在常规抗心衰治疗基础上加用阿托伐他汀,We investigated the effect of atovastatin on RAAS and inflammatory cytokines in patients with chronic heart failure（CHF）.Ninety three patients with CHF were randomly divided into two groups：control group treated with conventional therapy,and atovastatin group treated with atovastatin based on conventional therapy.There was significant difference in plasma levels of sACE2,ACE2-Ab,TNF-α,Ang（1-7）,IL-6,and NTproBNP before and after treatment in all groups（P〈0.05 or P〈0.01）.As compared with control group after treatment,the plasma levels of sACE2,ACE2-Ab,TNF-α,IL-6,and NT-proBNP after treatment in atovastatin group were decreased markedly（P〈0.05）.On the contrary,the concentration of Ang（1-7）was significantly higher（P〈0.01）.

关 键 词：慢性心力衰竭 阿托伐他汀 血管紧张素转化酶2 血管紧张素 炎性因子 

分 类 号：R541.4[医药卫生—心血管疾病]